Evidence map›Paper›PMID 39528456›Full record

ArticleJournal of the Chinese Medical Association : JCMA2025

Real-world outcomes of everolimus-based treatment in a Taiwanese cohort with metastatic HR+/HER2- breast cancer.

Yun-Chieh Kao, Yi-Fang Tsai, Shih-Che Shen, Ming-Shen Dai, Fang-Ming Chen, Liang-Chih Liu, Ta-Chung Chao, Chi-Cheng Huang, Ming-Feng Hou, Shin-Cheh Chen and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of the Chinese Medical Association : JCMA, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Article
  3. Optimizing outcomes for the patients with extensive-stage small-cell lung cancer.Journal of the Chinese Medical Association : JCMA · 2025
    Article
  4. Article
  5. Is C3c structure useful as biomarkers for epithelial ovarian cancer?Journal of the Chinese Medical Association : JCMA · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Yun-Chieh KaoDivision of Medical Oncology, Department of Oncology, Taipei Veterans General Hospital, Taipei, Taiwan, ROC.
Yi-Fang TsaiSchool of Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan, ROC.
Shih-Che ShenDivision of Breast Surgery, Department of General Surgery, Chang Gung Memorial Hospital, Taoyuan, Taiwan, ROC.
Ming-Shen DaiDivision of Hematology and Oncology, Tri-Service General Hospital, National Defense Medical Center, Taipei, Taiwan, ROC.
Fang-Ming ChenDivision of Breast Surgery, Department of Surgery, Kaohsiung Medical University Hospital, Kaohsiung, Taiwan, ROC.
Liang-Chih LiuDepartment of Surgery, China Medical University Hospital, Taichung, Taiwan, ROC.
Ta-Chung ChaoDivision of Medical Oncology, Department of Oncology, Taipei Veterans General Hospital, Taipei, Taiwan, ROC.
Chi-Cheng HuangSchool of Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan, ROC.
Ming-Feng HouDivision of Breast Surgery, Department of Surgery, Kaohsiung Medical University Hospital, Kaohsiung, Taiwan, ROC.
Shin-Cheh ChenDivision of Breast Surgery, Department of General Surgery, Chang Gung Memorial Hospital, Taoyuan, Taiwan, ROC.
Chun-Yu LiuDivision of Medical Oncology, Department of Oncology, Taipei Veterans General Hospital, Taipei, Taiwan, ROC.
Ling-Ming TsengSchool of Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan, ROC.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundEverolimus was the first orally targeted therapy for certain cancers. It was introduced before CDK4/6 inhibitors and is widely used to treat advanced hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-negative (HER2-) breast cancer. This study presents comprehensive findings including updated data and long-term survival analyses focusing on patients with HR+/HER2- metastatic breast cancer who received everolimus-based treatment. The objectives were to assess the impact of everolimus on overall survival (OS) and progression-free survival (PFS) by treatment line, and to evaluate its role in therapeutic strategies in a real-world setting.

methodsWe included 299 women aged over 20 years with histologically confirmed HR+/HER2- breast cancer who received everolimus-based treatment from multiple medical centers in Taiwan. Survival curves were generated using the Kaplan-Meier method, with the log-rank test for comparisons. Univariate and multivariate analyses were performed using a Cox proportional hazards regression model. Adverse effects were graded according to the Common Terminology Criteria for Adverse Events version 5.0.

resultsThe median PFS was 5.6 months, and the median OS was 60.1 months. Patients receiving everolimus treatment in three or more lines and those who underwent chemotherapy before everolimus-based treatment had a significantly shorter PFS but longer OS. Patients with liver and central nervous system metastases had significantly shorter PFS and OS. The disease control rate was 51.5%, and the overall response rate was 8.0%.

conclusionThese findings support current guidelines and advocate for the inclusion of everolimus in treatment plans for patients with metastatic HR+/HER2- breast cancer, particularly in late-line treatment, with careful consideration of the benefit-risk profile for each patient.

Indexed as

Breast NeoplasmsErb-b2 Receptor Tyrosine KinasesEverolimusAdultAgedAged, 80 and overAntineoplastic AgentsFemaleHumansMiddle AgedNeoplasm MetastasisReceptors, EstrogenReceptors, ProgesteroneRetrospective StudiesTaiwanAntineoplastic AgentsERBB2 protein, humanErb-b2 Receptor Tyrosine KinasesEverolimusReceptors, EstrogenReceptors, Progesterone

Identifiers

PMID39528456
PMCPMC12718841

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.